| Hazard Information | Back Directory | [Uses]
The CD73-antagonist antibody oleclumab inhibits cell surface-exposed CD73 and is currently undergoing clinical testing for cancer immunotherapy. | [in vivo]
Oleclumab (10 mg/kg; ip; every 3 days for 4 doses) increases the proportion of activated CD8+ lymphocyte populations in the mouse Balb/c syngeneic CT26 colon cancer tumor model. And Oleclumab significantly inhibits tumor growth[2].
| Animal Model: | Murine, Balb/c, syngeneic CT26 colon carcinoma tumor model[2] | | Dosage: | 10 mg/kg | | Administration: | ip; 2 time per week, for 2 weeks | | Result: | Inhibited tumor growth by 50% or greater from study day 7 to study day 16 when compared with isotype control antibody-treated groups.
|
|
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|